Sir, Assessment of a three-generation pedigree with Fuchs endothelial corneal dystrophy with anticipation for expansion of the triplet repeat in the TCF4 gene Fuchs endothelial corneal dystrophy (FECD) has a significant genetic component to its pathogenesis and several genetic risk factors for FECD have been discovered. The first genetic risk factor for FECD, transcription factor 4 (TCF4), was detected by a genomewide association study. 1 A trinucleotide repeat, (CTG) n also known as CTG18.1, is located within an intron of the TCF4 gene. 2 Expansion of the TCF4 trinucleotide repeat is associated with FECD and expansion to 440 repeats confers a hazards ratio of 1.64 for a corneal transplant. 3 Anticipation, earlier onset of disease with increasing severity in successive generations, occurs in diseases caused by trinucleotide repeat expansions (ie, Huntington's disease). 4 
Case report
We investigated the potential role of TCF4 trinucleotide repeat expansion in a three-generation pedigree with a history suggestive of anticipation. FECD was diagnosed via slit lamp biomicroscopy by a board-certified ophthalmologist with cornea fellowship training, graded using a modified Krachmer scale of 0 (no disease)-6 (45 mm of central confluent guttae with corneal edema), 5 and examined via confocal microscopy (ConfoScan 4, Nidek Technologies, Fremont, CA, USA) and corneal tomography (Pentacam HR, Oculus, Lynnwood, WA, USA).
Three family members were diagnosed with FECD 5 and displayed features of anticipation. The age at diagnosis occurred earlier in each successive generation, with the grandmother, mother, and daughter receiving the diagnosis of FECD at 63, 48, and 27 years of age, respectively (Figures 1 and 2 ). The severity of corneal endothelial disease was greater in each successive generation, with the grandmother, mother, and daughter displaying a modified Krachmer Grade of 2, 4, and 6, respectively, and central corneal thickness (right/left) of 535/537, 568/572, and 627/602 μm, respectively.
The size of the TCF4 trinucleotide repeat was evaluated in members of the FECD pedigree to determine if an expansion of the repeat might be the source of anticipation. The TCF4 trinucleotide repeat was amplified from family member DNA samples with the polymerase chain reaction, cloned, and sequenced using standard methods. 6 Each family member's genome has two copies of the TCF4 gene. Analysis of these DNA sequences revealed the exact number of TCF4 trinucleotide repeats in each family member's genome. The grandmother, mother, and 
Comment
All three family members with FECD had o40 TCF4 trinucleotide repeats. While larger numbers of TCF4 trinucleotide repeats confer higher risk for FECD, 20% of patients with FECD have fewer than 40 repeats as in this pedigree. 2 Moreover, there is no expansion of TCF4 trinucleotide repeats in successive generations of the pedigree (Figure 1 ). These data demonstrate that anticipation of FECD in this pedigree is not due to trinucleotide repeat expansion in the TCF4 gene. The earlier age at diagnosis and severity of FECD in offspring of this pedigree may be due in part to ascertainment bias and/or other genetic and environmental factors. However, the TCF4 trinucleotide repeat may underlie anticipation in other FECD pedigrees with patients that have larger numbers of repeats than were observed in this study.
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